<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-title-group><journal-title>Breast Cancer Research : BCR</journal-title></journal-title-group><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3247045</article-id><article-id pub-id-type="publisher-id">bcr3011</article-id><article-id pub-id-type="doi">10.1186/bcr3011</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Baselga</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Costa</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Gomez</surname><given-names>H</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Hudis</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Rapoport</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Roche</surname><given-names>H</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Schwartzberg</surname><given-names>LS</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Petrenciuc</surname><given-names>O</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Shan</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Gradishar</surname><given-names>WJ</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib></contrib-group><aff id="I1"><label>1</label>Massachusetts General Hospital Cancer Center, Boston, MA, USA</aff><aff id="I2"><label>2</label>Hosp Sirio Libanes, S&#x000e3;o Paulo, Brazil</aff><aff id="I3"><label>3</label>Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru</aff><aff id="I4"><label>4</label>Memorial Sloan-Kettering Cancer Center, New York, NY, USA</aff><aff id="I5"><label>5</label>The Medical Oncology Centre of Rosebank, Johannesburg, South Africa</aff><aff id="I6"><label>6</label>Institut Claudius Regaud, Toulouse, France</aff><aff id="I7"><label>7</label>West Clinic, Memphis, TN, USA</aff><aff id="I8"><label>8</label>Bayer HealthCare Pharmaceuticals, Toronto, ON, Canada</aff><aff id="I9"><label>9</label>Feinberg School of Medicine, Northwestern University, Chicago, IL, USA</aff><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub"><day>16</day><month>11</month><year>2011</year></pub-date><volume>13</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">IX Madrid Breast Cancer Conference</named-content></supplement><fpage>O12</fpage><lpage>O12</lpage><permissions><copyright-statement>Copyright &#x000a9;2011 Baselga et al.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Baselga et al.</copyright-holder></permissions><self-uri xlink:href="http://breast-cancer-research.com/content/13/S2/O12"/><conference><conf-date>16-17 November 2011</conf-date><conf-name>IX Madrid Breast Cancer Conference</conf-name><conf-loc>Madrid, Spain</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>A double-blind, randomized, phase 2b screening trial (SOLTI-0701) of sorafenib, an oral multikinase inhibitor, in patients with HER2-negative advanced breast cancer (BC), showed a statistically significant improvement in progression-free survival (PFS) in the sorafenib + capecitabine arm versus the placebo + capecitabine arm: 6.4 versus 4.1 months (hazard ratio = 0.58; one-sided <italic>P </italic>= 0.0006). Grade 3/4 toxicities were comparable except G3 hand-foot skin reaction/syndrome (HFSR/HFS) (44% vs. 14%). These results support a phase 3 trial of sorafenib + capecitabine in advanced BC.</p></sec><sec sec-type="methods"><title>Methods</title><p>RESILIENCE is an ongoing multinational, double-blind, placebo-controlled, phase 3 trial designed to assess sorafenib + capecitabine as first-line or second-line therapy in advanced HER2-negative BC (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">http://ClinicalTrials.gov</ext-link>, NCT01234337). Eligibility criteria include: &#x02265;18 years of age; &#x02264;1 prior chemotherapy regimen for advanced BC; resistant to/failed taxane and anthracycline or no indication for further anthracycline; no prior VEGF treatment. Patients are randomized to capecitabine (1,000 mg/m<sup>2 </sup>p.o. twice daily, days 1 to 14 of 21) with sorafenib (p.o. twice daily, days 1 to 21, total dose 600 mg/day) or placebo. Sorafenib 600 mg/day corresponds to the average daily dose during SOLTI-0701 that was effective and manageable. Doses can be escalated to 2,500 mg/m<sup>2 </sup>and 800 mg/day or reduced to manage toxicity. Dose re-escalation after reduction is only allowed for sorafenib/placebo. Guidelines detail prophylactic and symptomatic therapy for HFSR/HFS. Radiographic assessment is every 6 weeks for 36 weeks, then every 9 weeks. The primary endpoint is PFS. Secondary endpoints include overall survival, time to progression, overall response rate, and duration of response. Enrollment began in November 2010 and targets ~519 patients.</p></sec><sec><title>Conclusion</title><p>RESILIENCE will provide definitive PFS data for sorafenib + capecitabine as first-line or second-line therapy in HER2-negative advanced BC and will better characterize the benefit-to-risk profile of this regimen.</p></sec></body></article>